KAMADA APPLIES FOR LICENSE FOR API CLINICAL TRIALS

Israel-based biopharmaceutical company Kamada has applied for a FDA license for the production of its Alpha 1-Proteinase Inhibitor (API) for Phase III clinical trials.

API is used for chronic replacement therapy for individuals with congenital deficiency of Alpha 1-Proteinase Inhibitor with demonstrable panacinar emphysema. Preliminary distribution of Kamada's API is now underway in several countries.